Abstract
Objectives Ketone bodies are endogenous metabolites produced during fasting or a ketogenic diet that have pleiotropic effects on aging pathways. Ketone esters (KEs) are compounds that induce ketosis without dietary changes, but KEs have not been studied in an older adult population. The primary objective of this trial was to determine tolerability and safety of KE ingestion in older adults.
Design Randomized, placebo-controlled, double-blinded, parallel-arm trial, with a 12-week intervention period (NCT05585762).
Setting General community, Northern California, USA.
Participants Community-dwelling older adults, independent in activities of daily living, with no unstable acute medical conditions (n=30) were randomized and n=23 (M= 14, F=9) completed the protocol.
Intervention Participants were randomly allocated to consume either KE (bis-octanoyl (R)-1,3-butanediol) or a taste, appearance, and calorie-matched placebo (PLA) containing canola oil.
Measurements Tolerability was assessed using a composite score from a daily log for 2-weeks, and then via a bi-weekly phone interview. Safety was assessed by vital signs and lab tests at screening and weeks 0, 4 and 12, along with tabulation of adverse events.
Results There was no difference in the prespecified primary outcome of proportion of participants reporting moderate or severe nausea, headache, or dizziness on more than one day in a two-week reporting period (KE n =2 (14.3% [90% CI = 2.6 – 38.5]); PLA n=1 (7.1% [90% CI = 0.4 – 29.7]). Dropouts numbered four in the PLA group and two in the KE group. A greater number of symptoms were reported in both groups during the first two weeks; symptoms were reported less frequently between 2 – 12 weeks. There were no clinically relevant changes in safety labs or vital signs in either group.
Conclusions This KE was safe and well-tolerated in healthy older adults. These results provide a foundation for use of KEs in aging research.
Ketones esters induce ketosis without dietary changes and may target aging biology
Studies of ketone esters were limited in duration and focused on younger adults
We found ketone esters were safe and tolerable for 12 weeks in healthy older adults
Competing Interest Statement
The principal investigator (Dr. Newman), Dr. Brianna Stubbs, and the Buck Institute hold shares in BHB Therapeutics. Drs. Newman (US 11,773,051 B2, US 11,608,306 B2) and Stubbs (US 11,645,228 B2) are inventors on patents relating to the use of ketone bodies that are assigned to The Buck Institute. All other authors have no conflicts to declare. Individual and institutional conflict management plans were developed and approved by the Buck Institute and submitted to the reviewing IRB. Actions and decisions important to participant safety and study integrity were carried out by 'honest brokers' with no potential financial conflict. Participant consent was obtained by licensed registered nurses (L.A and W.S.M) who have no financial conflict. Decisions on participant enrollment, continuation, and were made by independent medical officers (J.M and M.Y) unaffiliated with Buck Institute and with no financial conflict. Data analysis for the primary outcome was carried out by an independent statistician with no financial conflict (T.B).
Clinical Trial
NCT05585762
Clinical Protocols
https://www.medrxiv.org/content/10.1101/2023.10.25.23297571v1.article-info
Funding Statement
Funding for the study was provided by philanthropic donations from Dr. James B. Johnson and from members of the Buck Institute Impact Circle. Dr. Johnson assisted with conceptualization of the study and reviewed this manuscript but has no further role in study design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications. The Buck Institute Impact Circle had no role in conceptualization, study design, management, data collection, analysis, interpretation of data, decision to submit publications, review, or writing of publications. Dr. Newman's participation in the study was supported by Buck Institute institutional funds. Dr. Brianna Stubbs' participation in the study was supported by the NIH (NIA) under award number K01AG078125. The KE intervention was provided gratis by BHB Therapeutics Ltd (Ireland). BHB Therapeutics also arranged for manufacture of the matched placebo, paid for by study funds. BHB Therapeutics markets formulated KE beverages to consumers. BHB Therapeutics provided no funding for the study, and had no role in the design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study, and all study material was approved by Advarra IRB (WIRB-Copernicus Group, Puyallup, WA, ID# 20213716, current version 1.3 approved on 16th October 2023)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- ALT
- Alanine Transaminase
- AST
- Aspartate Aminotransferase
- BH-BD
- Bis-hexanoyl (R)-1,3-butanediol
- BHB
- Beta-hydroxybutyrate
- BIKE
- Buck Institute Ketone Ester
- BMI
- Body Mass Index
- BO-BD
- Bis-octanoyl (R)-1,3-butanediol
- BTQ
- Beverage Tolerability Questionnaire
- CI
- Confidence Interval
- GI
- Gastrointestinal
- HDL
- High Density Lipoprotein
- ITT
- Intent to Treat
- KE(s)
- Ketone Ester(s)
- LDL
- Low Density Lipoprotein
- MCT
- Medium Chain Triglyceride
- PLA
- Placebo
- PP
- Per Protocol
- T4
- Thyroxine
